sinopharm

Due to the rapid launch and development of vaccines (the most ideal protocol for countering COVID-19), monitoring of post-vaccination side effects is essential. This study aimed to assess symptoms and side effects of three types of COVID-19 vaccines (Sputnik, AstraZeneca, and Sinopharm) and the details of their relationship with demographic characteristics in Iran.

A cross-sectional and telephonic interview-based study was conducted from May 12 to July 11, 2021, among 420 university staff who received both doses of the COVID-19 vaccine. The association of vaccination behavior-related symptoms after the first and second doses with age, gender, vaccine type, blood type, underlying medical situation, and past infection and reinfection with SARS-CoV-2 was analyzed.

The majority of participants were men (58.7%), the median age was 41.30+11.208 years, and 18.6% were vaccinated with the Sputnik vaccine, 75.1% with Sinopharm, and 6.3% with AstraZeneca. In addition, 47.3% and 41.8% were symptomatic after first and second dose vaccination, respectively. The frequency of symptoms was higher in younger individuals, women, and AstraZeneca recipients (p = 0.001). The most frequently reported symptoms were fever, weakness, and muscular and injection site pain. These symptoms were more reported after the first dose than the second one. There was no significant connection between blood types, underlying medical situations, past infection and reinfection with SARS-CoV-2, and the prevalence of symptoms.

AstraZeneca, Sputnik, and Sinopharm COVID-19 vaccines were found to be safe and the lowest incidence of symptoms was seen in Sinopharm recipients.

COVID-19 infection during pregnancy could be associated with placental histopathological changes such as vascular diseases and malperfusion. There are studies showing that mRNA vaccines are not associated with significant placental pathological changes. Our objective was to evaluate the placental histopathology in pregnant women who received Sinopharm, an inactivated virus vaccine, during pregnancy.

The study included placental samples collected from mothers who gave birth of living singletons through elective cesarean sections performed between March 2022 and May 2022 at Imam Khomeini Hospital Complex. The study included women who had no history of positive reverse transcription polymerase chain reaction (RT-PCR) testing for COVID-19 during pregnancy, and had received at least one dose of COVID-19 vaccine during their pregnancy. Humoral levels of anti-SARS-CoV-2 spike IgG were measured in both the mothers and neonates.

The study included 20 mother-neonate pairs. The mean maternal age was 34±3.6 years, and all mothers received Sinopharm vaccine as their first and second doses. The last vaccine dose was administered during pregnancy, with 3 mothers receiving it in the first trimester, 9 in the second trimester, and 8 in the third trimester. The histopathological findings in the placental samples included decidual vasculopathy, subchorionic thrombosis, and chronic histiocytic intervillositis. All mothers and neonates, except one pair, were positive for anti-spike antibody.

Multiple abnormal histopathological findings were reported in placenta of vaccinated mothers. However, similar to previous studies, these placental findings are considered mild lesions and have been observed in both vaccinated and unvaccinated mothers.

The seroconversion rate is lower in response to COVID-19 vaccination in immunocompromised patients.

This study aimed to investigate the humoral immune response and short-term clinical outcomes in kidney transplant recipients vaccinated with the SARS-CoV-2 vaccine (BBIBP-CorV; Sinopharm).

This prospective cohort was conducted from May to December 2021 in Abu Ali Sina Hospital, Iran. All kidney transplant recipients older than 18 received two doses of the Sinopharm vaccine four weeks apart. Immunogenicity was assessed by evaluating antibodies against the receptor-binding domain (RBD) of SARS-CoV-2 after the first and second vaccine doses. Patients were followed up for six months after vaccination.

Out of 665 kidney transplant patients, 76 patients (11.43%) and 182 patients (27.37%) had acceptable anti-S-RBD immunoglobulin G (IgG) levels after the first and second doses. Forty-six patients (6.91%) were infected with COVID-19, which led to the hospitalization of 34 (5.11%) of them. No deaths were recorded during the follow-up period. An increase in serum creatinine was detected in 86 (12.93%) studied patients. The predominant adverse reactions reported in patients were fatigue, headache, and injection site pain.

Our findings showed that the humoral response rate of kidney transplant recipients to the Sinopharm vaccine is relatively low, and receiving the third dose of the vaccine seems reasonable to a large extent. Also, the care of the COVID-19 disease in people who are in the first year after receiving a kidney transplant should be more accurate and intensive.

Vaccination against COVID-19 for people with multiple sclerosis (PWMS) has been recommended, but long-term follow-up needs further research.

To follow up PWMS 3 months after vaccination with the Sinopharm vaccine regarding the relapse of MS and infection with COVID-19.

The participants in this prospective study were PWMS over 18 years of age living in Kermanshah Province, Iran, who received two doses of the Sinopharm vaccine between August and November 2021. The information on demographic and clinical characteristics of PWMS, COVID-19 infection, and relapses of MS 3 months after vaccination, were collected. We contacted the patients using the information registered in the MS registry system of Kermanshah Province, and the study data were collected by phone call and using a researcher-made questionnaire.

Overall, 197 MS patients with a Mean±SD age of 41.84±11.0 years, including 155(78.7%) females and 42(21.3%) males were studied. There was no significant difference (P=1.000) in MS relapse frequency between the time points of 3 months before the first dose (15[7.6%]) and 3 months after the second dose (15[7.6%]). The frequency of infection with COVID-19 within 3 months after the second dose (26[13.2%]) was significantly (P=0.017) higher than that in the 3 months before the first dose (12[6.1%]). Within 3 months after the second dose, most PWMS with MS relapse or COVID-19 infection used oral and anti-CD20 therapy.

During the 3 months after the second dose, the frequency of MS relapse was not different, but the frequency of COVID-19 infection was higher.

Clinical trials were conducted on children on side effects after vaccination. We tried to assess the frequency and onset of the main symptoms in children who were vaccinated. We aimed to evaluate early and delayed adverse effects after coronavirus disease 2019 (COVID-19) vaccine among Iranian pediatrics and adolescents in a national survey.  

This cross-sectional study included people <18 years who received the Soberana (PastoCoVac) and Sinopharm vaccines since 2021. The basic information was gender, age, type of vaccine, and reaction after vaccination besides the main events that occurred for them. The required data were collected via a predetermined checklist by trained interviewers through phone calls by their parents or legal guardians. The independent t test and Fisher exact test were used. P values less than 0.05 were considered significant. 

A total of 11,042 participants (age range, 10-18 years) consisting of 5374 boys (47.8%) and 5768 girls (52.2%) were studied and 88.1% of the children (n = 9727) were vaccinated by Sinopharm and 11.9% (n = 1315) by Soberana. The data of kidney-related side effects had delayed improvement of side effects after the Sinopharm compared with the Soberana vaccines (P = 0.012). Cardiovascular and hematological side effects showed early-onset (P = 0.006) and delayed improvement of side effects (P = 0.002) after the Soberana vaccine compared with the Sinopharm vaccine. Neurological side effects showed delayed improvement of side effects after the Soberana vaccine compared with the  Sinopharm vaccine (P = 0.027). Joint-related side effects showed early-onset (P = 0.004) and delayed improvement of side effects (P = 0.023) after the Soberana vaccine compared with the Sinopharm vaccine. Respiratory side effects showed delayed improvement of side effects after the Soberana vaccine compared with the Sinopharm vaccine (P = 0.013), and dermatological side effects showed early-onset (P = 0.050) and delayed improvement of side effects (P = 0.035) after the Soberana vaccine compared with the Sinopharm vaccine. There was not any statistically significant difference regarding gastrointestinal side effects between the 2 vaccines (P > 0.05).

The cardiovascular and hematological, joint-related (non-neurologic musculoskeletal) and dermatological side effects after the Soberana vaccine appear earlier and end later compared with the Sinopharm vaccine. Improvement of renal side effects in the Sinopharm vaccine group and improvement of neurological and respiratory side effects in the Soberana vaccine group occurred with delay compared with other vaccines.

 COVID-19 infection may be associated with potential sequels on the hormonal system, which can substantially alter menstrual cycles in women.

 This study aimed to evaluate short-term menstrual distributions after COVID-19 infection and determine whether vaccination and type of vaccine could alter menstrual cycles.

 This study was carried out using an online survey to record any menstrual distributions such as any changes in duration, volume, and time of menstruation, intermenstrual bleeding (IMB) and dysmenorrhea as well as exacerbation of premenstrual syndrome (PMS) on 268 women aged 18 to 45 who were infected by COVID-19. The participants were followed at least for three months after their COVID-19 infection. The history of vaccine administration before infection was also recorded, and the results were compared regarding various vaccine types.

 Short-term menstrual distributions after infection were common. in this regard46.7% had IMB, 66.1% experienced exacerbation in PMS, 67.7% had increased volume of bleeding, 62.9% had dysmenorrhea or exacerbation in dysmenorrhea. Also, 27.4% and 35.4% experienced a shorter or longer duration of menstrual cycles, respectively. All distributions returned to normal after a maximum of two cycles. However, there was a substantial difference (P = 0.024) between women who received the AstraZeneca (recombinant) and Sinopharm (inactivated) vaccines, as the number of patients who experienced changes in menstrual cycles was relatively lower in the recombinant group.

 Menstrual distributions are common but temporary in the short term following COVID-19 infection. Although, the recombinant vaccine (AstraZeneca) was associated with lower menstrual disturbance rates compared to Sinopharm or Sputnik vaccines.

Coronavirus 2019 (COVID-19) vaccination is recommended for people with multiple sclerosis (MS). This study evaluated the side effects of Sinopharm and AstraZeneca vaccines in MS patients.

In this cross-sectional study among MS patients in Kermanshah province, Iran, who received Sinopharm or AstraZeneca vaccine, sampling was performed through convenience sampling according to the nationwide MS registry of Iran (NMSRI). Demographic and clinical information of the participants and data on the side effects of vaccines were collected by telephone after the first dose. The data were analyzed in SPSS software.

264 vaccinated MS patients (217 with Sinopharm and 47 with AstraZeneca) were studied. In the Sinopharm and AstraZeneca groups, respectively, 58.5% and 73.3% of patients had side effects that were not significantly different between the 2 groups (P = 0.064). In the AstraZeneca group, the severity of side effects and prevalence of taking painkillers were significantly higher (P < 0.050) and the interval between vaccination and side effects onset was significantly shorter (P = 0.013). The most commonly experienced side effects in the Sinopharm group were fatigue (29.0%), myalgia (24.9%), fever (24.0%), and headache (21.7%), and in the AstraZeneca group were fever (59.6%), chills (51.1%), myalgia (40.4%), and fatigue (34.0%). Logistic regression by controlling for confounding variables showed that considering some factors as confounding factors did not show a significant difference between the 2 vaccines in the experience of side effects (P = 0.104).

The AstraZeneca vaccine caused more severe side effects in MS patients than the Sinopharm vaccine. Most of the side effects were moderate in severity and transient.

This study aimed to investigate the incidence of rheumatoid arthritis (RA) flare-ups following immunization with the Sinopharm COVID-19 inactivated virus-based vaccine.

We conducted a retrospective observational study at the Rheumatology Clinic of Imam Hossein Hospital, incorporating 200 RA patients in remission undergoing non-biologic Disease-Modifying Antirheumatic Drugs (DMARDs) treatments. A rheumatologist confirmed a flare-up based on patients complain of arthralgia and joint stiffness and complete examination of joints over a three-month period following vaccination.

Twelve percent of all included patients experienced symptom recurrence. The average age of patients with flare-ups was significantly higher, but no gender-based differences were observed (p<0.001 and p=0.071, respectively). The second vaccine dose resulted in a higher number of symptom flares compared to the first dose (9.30% vs. 3.0%, p < 0.001). No significant differences were observed between patients experiencing flare-ups after the first dose and the second dose in terms of the number of involved joints (p=0.321) and the time gap from vaccination to symptom recurrence (p=0.526). No patients required hospitalization, and prednisolone dosage adjustments effectively managed symptoms.

The occurrence of flare-ups was relatively low after the Sinopharm COVID-19 vaccination in RA patients undergoing treatment with DMARDs during remission. The majority of these flares were mild and no hospitalizations were required. 

There are limited reports of oculomotor nerve palsy following vaccination. Herein, we aimed to report a case of acute oculomotor nerve palsy following the first dose of the Sinopharm vaccine. A 17-year-old woman presented with a history of acute painful diplopia and right ptosis within a week after receiving the first dosage of the Sinopharm vaccine. The neurological examination was compatible with acute right third nerve palsy sparing pupils. All the para-clinical tests were unremarkable. With a diagnosis of possible oculomotor nerve palsy as an adverse event of the COVID-19 vaccine, she was treated with steroids leading to a significant recovery. We reported the first case of acute oculomotor nerve palsy associated with the Sinopharm vaccine. However, our findings dose not conclude a causal association between oculomotor nerve palsy and COVID-19 vaccination.

Following the coronavirus disease 2019 (COVID-19) vaccination, complications are expected. In this regard, coagulopathy after COVID-19 vaccination has been reported. Here, we report a rare case of ischemic stroke subsequent to receiving the Beijing Bio-Institute of Biological Products - Coronavirus (BBIBP-CorV) vaccine (Sinopharm). Ten days after receiving the first dose of the BBIBP-CorV vaccine, a 76-year-old woman showed right central hemifacial weakness, balance disorder, and right hemisensory involvement with normal muscle force. Although the magnetic resonance imaging assessment revealed an acute lacunar stroke in her left thalamus, laboratory findings were normal. Based on our report, ischemic stroke may be a post-complication of BBIBP- CorV vaccination. However, further studies are needed to confirm this finding.

To report unilateral acute‑onset central serous chorioretinopathy (CSC) following vaccination with inactivated coronavirus disease 2019 (COVID-19) vaccine in a healthy patient.

Case report and review of literature.

A 39‑year‑old male was referred with sudden‑onset, painless, unilateral blurred vision in the right eye. His first dose of the Sinopharm vaccine was injected 2 days before. A complete ocular examination revealed central subretinal fluid (SRF) accumulation in favor of CSC in the right eye. Systemic workup disclosed no previous COVID‑19 infection or any systemic involvement. After 3 weeks, SRF decreased remarkably without treatment.

It is proposed that CSC development can be an ocular adverse effect of COVID‑19 vaccination, although it is infrequent. Ophthalmologists should be aware of the possible association between COVID‑19 vaccination and ocular adverse effects, but vaccination is the best effectual measure against COVID‑19.

An old-aged woman was evaluated with branch retinal vein occlusion (BRVO) vision reduction in his left eye three weeks after the Sinopharm coronavirus disease 2019 (COVID-19) vaccination. Her best-corrected visual acuity (BCVA) was 1m counting finger in the left eye and 10/10 in the right eye. Initial retinal findings were superior retinal hemorrhage with prominent retinal vein dilation and tortuosity in the left eye. Fluorescein angiography (FA) and optical coherence tomography (OCT) confirmed a BRVO diagnosis. Blood reports showed no abnormalities. Antithrombotic treatment of 80 mg/d low-dose entrocoated ASA was administered. In addition, an intravitreal Aflibercept (Eylea) injection, monthly and ongoing, was prescripted, which led to a decrease in macular edema, retinal hemorrhage, and height of serous retinal detachment. Moreover, theBCVAimproved to 2/10 after a three-week followup.

Despite several challenges, the SARS-CoV-2 pandemic is still not over. Rapid mass-scale immunization is critical to prevent further COVID-19-associated deaths.

Herein, we aimed to evaluate the rapid ramp-up effects of spike antibodies in response to Sputnik V, Sinopharm, and SinoVac first dose administration in the general public of Pakistan.

A cross-sectional study was conducted on 2000 participants to examine Sputnik V, Sinopharm, and SinoVac first dose effects 21 days post-administration. From 1200 real-time PCR negative subjects, the samples were subjected to SARS-CoV-2 spike antibody levels using electro-chemiluminescence immunoassay (ECLIA) (Elecsys, # 09289267190 Roche, USA).

SARS-CoV-2 spike protein positivity was detected highest at 87% among participants receiving SputnikV with SARS-CoV-2 spike protein antibodies > 1.5 AU/mL compared to 47.6% and 25% in individuals receiving Sinopharm and SinoVac, respectively. Also, 36.04% of the Sputnik-administered individuals depicted antibody levels > 250 AU/mL. Of the participants, 55% had a previous history of COVID-19. Also, 14.86%, 4.76%, and 0% of the SputnikV, Sinopharm, and SinoVac administered subjects showed antibodies > 100 AU/mL, respectively, while > 25 AU/mL antibodies were found in 10.70% of SputnikV, 19.04% of Sinopharm and 10.71% of SinoVac administered individuals. Moreover, > 1.5 - 2.5 AU/mL antibodies levels were found in 25.10%, 23.80%, and 14.28% of participants with SputnikV, Sinopharm, and SinoVac administered vaccines, respectively. The antibody titers of < 1.5 AU/mL were detected among 13.30%, 52.38%, and 46.42% of subjects administered with SputnikV, Sinopharm, and SinoVac vaccines, respectively.

Even before administrating the second booster dose of SputnikV, a significantly higher number of patients depicted rapid ramp-up of SARS-CoV-2 specific spike antibodies, which can significantly contribute to rapid mass-immunization. Despite all challenges, persistent antibody plateau monitoring is critical to attaining humoral immunity against SARS-CoV-2 infections.

 Vaccines are the most effective way to prevent Coronavirus 2 severe acute respiratory syndrome (SARS-CoV-2). To compare the antibody response of healthy individuals vaccinated with either the AstraZeneca (ChAdOx1 nCoV-19) or the Sinopharm (BBIBP-CorV) vaccine, in those who had no prior infection with SARS-CoV-2. Thirty seven participants were included, of which 17 were administered the AstraZeneca (ChAdOx1 nCoV-19) vaccine, while 20 were given the Sinopharm (BBIBP-CorV) vaccine. SARS-CoV-2 neutralizing antibody and anti-receptor-binding domain (RBD) IgG levels were checked 4 weeks after giving the first and the second dose of either vaccine using the enzyme-linked immunosorbent assay (ELISA) technique. The AstraZeneca (ChAdOx1 nCoV-19) vaccine exhibited a higher levels of anti-(RBD) IgG compared with the Sinopharm (BBIBP-CorV) in both the first (14.51 μg/ml vs. 1.160 μg/ml) and the second (46.68 μg/ml vs. 11.43 μg/ml) doses. About neutralizing Abs, the titer of the antibody was higher in the AstraZeneca (ChAdOx1 nCoV-19) recipients than in the Sinopharm (BBIBP-CorV) subjects after the first (7.77 μg/ml vs. 1.79 μg/ml, p < 0.0001) and the second dose (10. 36 μg/ml vs. 4.88 μg/ml, p < 0.0001). Recipients vaccinated with two doses of the AstraZeneca (ChAdOx1 nCoV-19) had superior quantitative antibody levels than Sinopharm (BBIBP-CorV)-vaccinated subjects. These data suggest that a booster dose may be needed for the Sinopharm (BBIBP-CorV) recipients, to control the COVID-19 pandemic.

The occurrence of side effects of vaccines plays an important role in their acceptance by people. Therefore, the aim of this study was to evaluate the side effects of COVID-19 vaccines (Sputnik-V, AstraZeneca, and Sinopharm) in Neyshabur health care workers (HCWs).

A cross-sectional study was performed to evaluate the side effects of COVID-19 vaccines among the HCWs of the Neyshabur University of Medical Sciences from July 31, 2021, to September 6, 2021, by using a self-report checklist. We sent our checklist via an internet link to collect data such as demographic data of participants, previous COVID-19 infection (PCR+), vaccine information and side effects of vaccines. Mean, median and standard deviation were used to determine descriptive statistics and a logistic regression model was also used to determine the relationship between the type of vaccine and its side effects.

317 participants filled out the checklist; among them 47% (N= 149), 21.14% (N= 67), and 31.86% (N= 101) have been vaccinated with Sputnik-V, AstraZeneca, and Sinopharm, respectively. The percentage of side effects after the first dose was 62.15% (N= 197). The Percentage of local side effects was 76% (N= 241) and systemic side effects were 29.36% (N= 95). The most common side effects in all three vaccines were injection site pain (75.08%, N= 240), muscle pain (62.46%, N=198) and headache (52.05%, N=165). Also, the odds ratio of injection site pain, chill and sweating in those who received the AstraZeneca vaccine was 3.9(95% CI, 1.7-9.3), 3.7 (95% CI, 1.8-7.3), and 3.2 (95% CI, 1.7-63), of those who received the Sputnik V vaccine (p ≤ 0.001).

The most common side effects among our participants were injection site pain, muscle pain, and headache. Most of the post-vaccination side effects are mild to moderate in severity and self-limited. Reported side effects were more common in recipients with AstraZeneca than in those with Sputnik-V and Sinopharm.

Context:

 Iran was one of the first countries in the world to encounter acute respiratory syndrome coronavirus 2 in February 2020. Numerous efforts have been made worldwide to develop safe and effective vaccines to prevent coronavirus disease 2019 (COVID-19). Finally, several vaccines with different platforms have been licensed for use in various countries. The injection of these vaccines can lead to a range of unwanted side effects (mild to severe).

 This study tried to collect the common adverse effects of the most frequently used COVID-19 vaccines in Iran and provide readers with relevant information and statistics.

 This review study collected papers by searching in foreign journals using databases, such as PubMed, PubMed Central, MEDLINE, EBSCO, Google Scholar, and Embase, with the keywords of side effects, COVID-19, vaccine, AstraZeneca, Sputnik V, and Sinopharm, which were published within 2000-2021.

 According to available information and studies, vaccines, unlike COVID-19, do not have any threatening and high-risk side effects, and their benefits outweigh their insignificant side effects. A total of 48 full-text studies and 10 valid websites with high citations and up-to-date information were selected. Among the relevant references, 26, 16, and 16 studies performed on AstraZeneca, Sputnik V, and Sinopharm vaccines were chosen for review, respectively.

 The findings of this study can reassure readers and be effective in combating misconceptions about vaccination. Undoubtedly, the main solution to overcome the economic damage and social health burden caused by the COVID-19 pandemic is to accelerate global vaccination.

Guillain-Barre Syndrome (GBS) is an autoimmune acute inflammatory demyelinating polyneuropathy usually elicited by an upper respiratory tract infection. Several studies reported GBS associated with Coronavirus Disease 2019 (COVID-19) infection. In this study, we described nine GBS patients following the COVID-19 vaccine.

In this study, nine patients were introduced from six referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients received the Sputnik V, three patients received the Sinopharm, and two cases received the AstraZeneca vaccine. All patients were diagnosed with GBS evidenced by nerve conduction studies and/or cerebrospinal fluid analysis.

The median age of the patients was 54.22 years (ranged 26-87 years), and seven patients were male. The patients were treated with Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PLEX). All patients were discharged with some improvements.

The link between the COVID-19 vaccine and GBS is not well understood. Given the prevalence of GBS over the population, this association may be coincidental; therefore, more studies are needed to investigate a causal relationship.